Rapid killing of M. leprae by moxifloxacin in two patients with lepromatous leprosy

Leprosy Review

Volumn 80, Issue 2, 2009, Pages 205-209

  Pardillo, F E Eleanor F ^a   Burgos, Jasmin ^a   Fajardo, Tranquilino T ^a   Dela Crux, Eduardo ^a   Abalos, Rodolfo M ^a   Paredes, Rose Maria D ^a   Andaya, Cora Evelyn S ^a   Gelber, Robert H ^a,b  

^a Leonard Wood Memorial Center for Leprosy Research Philippines   (Philippines)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; MOXIFLOXACIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BACTERIAL VIABILITY; CASE REPORT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HUMAN TISSUE; LEPROMATOUS LEPROSY; MALE; MYCOBACTERIUM LEPRAE; NEURITIS; REVERSAL REACTION; SINGLE DRUG DOSE; SKIN BIOPSY; SKIN DEFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AZA COMPOUNDS; HUMANS; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; MALE; MICROBIAL VIABILITY; MIDDLE AGED; MYCOBACTERIUM LEPRAE; QUINOLINES; SKIN; TREATMENT OUTCOME;

EID: 70349191553     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Pardillo FEF, Burgos J, Fajardo TT et al. Powerful bactericidal activity of moxifloxacin in human leprosy. Antimicrob Agents Chemother, 2008; 52: 3113-3117.
2. N'Deli L, Guelpa-Lauras CC, Perani EG, Grosset JH. Effectiveness of pefloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis, 1990; 58: 23-28. (Pubitemid 20129564)
3. Grosset JH, Ji B, Guelpa-Lauras CC et al. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis, 1990; 58: 281-295. (Pubitemid 20234056)
4. Fajardo TT, Villahermosa LG, Dela Cruz EC et al. A clinical trial of pefloxacin and ofloxacin in lepromatous leprosy. Lepr Rev, 2005; 73: 389-391.
5. Gelber RH, Fukuda K, Byrd S et al. A clinical trial of minocycline in lepromatous leprosy. Br Med J, 1992; 304: 91-92.
6. Fajardo TT, Villahermosa LG, Dela Cruz EC et al. Minocycline in lepromatous leprosy. Int J Lepr Other Mycobact Dis, 1995; 63: 8-17.
7. Chan GP, Garcia-Ignacio BY, Chavez EV et al. Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob Agents Chemother, 1994; 38: 515-517.
8. Shepard CC. A brief review of experiences with short-term clinical trials monitored by mouse-foot-pad inoculation. Br Lepr Relief Assoc, 1981; 52: 299-308.
9. Ridley DS, Jopling WH. Classification of leprosy according to immunity: a five-group system. Int J Lepr Other Mycobact Dis, 1966; 34: 255-273.
10. Shepard CC, McRae DH. A method for counting acid-fast bacilli. Int J Lepr Other Mycobact Dis, 1968; 36: 78-82.
11. Shepard CC. Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae. Int J Lepr Other Mycobact Dis, 1982; 50: 96-101.
12. East African/British Medical Research Council. Controlled clinical trail of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet, 1974; 2: 110-1106.
13. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Am Re Respir Dis, 1978; 118: 219-227.
14. Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med, 2003; 67: 603-662.
15. Gelber RH, Balagon VF, Cellona RV. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis, 2004; 72: 493-500.
16. Pattyn S, Grillone S. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. Lepr Rev, 2002; 73: 245-247.
17. Matsuoka M, Budiawan T, Aye KS et al. The frequency of drug resistant mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients in Myanmar, Indonesia, and the Philippines. Lepr Rev, 2007; 78: 343-352.